Tempus AITEM stock briefly jumped into a profit-taking zone Thursday after the Food and Drug Administration cleared its updated cardiac-imaging platform, Tempus Pixel. The platform uses artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback